Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice

Gene Therapy

Volumn 10, Issue 14, 2003, Pages 1170-1178

  Dancer, A ^a   Julien, S ^a   Bouillot, S ^a   Pointu, H ^b   Vernet, M ^b   Huber, P ^a  

^a CEA GRENOBLE   (France)

^b DRDC   (France)

Author keywords

Angiogenesis inhibitors; Endothelium; Ganciclovir; Lewis lung carcinoma; Thymidine kinase; Transgenic mice

Indexed keywords

CADHERIN; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOMA CELL; CELL DEATH; CELL DIVISION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HERPES SIMPLEX VIRUS; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STATISTICAL SIGNIFICANCE; SUICIDE GENE THERAPY; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CADHERINS; CARCINOMA, LEWIS LUNG; ENDOTHELIUM, VASCULAR; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; THYMIDINE KINASE;

ANIMALIA; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0042309754     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301981     Document Type: Review

References (80)

1. Folkman J. Angiogenesis and breast cancer. J Clin Oncol 1994; 12: 441-443.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases Nature 2000; 407: 249-257.
4. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments]. N Engl J Med 1995; 333: 1757-1763.
5. O'Reilly MS et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
6. O'Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
7. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17-38.
8. Bouma-ter Steege JC, Mayo KH, Griffioen AW. Angiostatic proteins and peptides. Crit Rev Eukaryot Gene Exp 2001; 11: 319-334.
9. Hohenester E, Sasaki T, Mann K, Timpl R. Variable zinc coordination in endostatin. J Mol Biol 2000; 297: 1-6.
10. Dhanabal M et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189-197.
11. Jouanneau E et al. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 2001; 51: 11-18.
12. Lynch CM et al. Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997; 80: 497-505.
13. Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther 2000; 7: 368-376.
14. Qian HS et al. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res 2001; 88: 911-917.
15. Ma Z et al. Redirecting adenovirus to pulmonary endothelium by cationic liposomes. Gene Ther 2002; 9: 176-182.
16. Lin P et al. Antiangiogenic gene therapy targeting the endothe-lium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-8834.
17. Blezinger P et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999; 17: 343-348.
18. Compagni A et al. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000; 60: 7163-7169.
19. Feldman AL et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000; 60: 1503-1506.
20. Jin RJ et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000; 7: 1537-1542.
21. Sacco MG et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther 2001; 8: 67-70.
22. Ding I et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 2001; 61: 526-531.
23. Kuo CJ et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-4610.
24. Gyorffy S, Palmer K, Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol 2001; 159: 1137-1147.
25. Hampl M et al. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther 2001; 12: 1713-1729.
26. Jin X et al. Evaluation of encdostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther 2001; 8: 982-989.
27. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther 2000; 2: 433-440.
28. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36.
29. Allen RG et al. Targeted ablation of pituitary pre-proopiomelanocortin cells by herpes simplex virus-1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Mol Endocrinol 1995; 9: 1005-1016.
30. Hood JD et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407.
31. Hirano T et al. HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Ther 2001; 8: 80-83.
32. Ido A et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021.
33. Tronik-Le Roux D et al. Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by the platelet glycoprotein alpha IIb promoter. J Exp Med 1995; 181: 2141-2151.
34. Vandier D et al. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther 2000; 7: 1120-1126.
35. Lee EJ et al. Adenovirus-mediated targeted expression of toxic genes to adrenocorticotropin-producing pituitary tumors using the proopiomelanocortin promoter. J Clin Endocrinol Metab 2001; 86: 3400-3409.
36. Zhang R, Straus FK, DeGroot LJ. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 2001; 11: 115-123.
37. Selvakumaran M et al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001; 61: 1291-1295.
38. Lampugnani MG et al. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992; 118: 1511-1522.
39. Breviario F et al. Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vasc Biol 1995; 15: 1229-1239.
40. Breier G et al. Molecular cloning and expression of murine vascular, endothelial-cadherin in early stage development of cardiovascular system. Blood 1996; 87: 630-641.
41. Liao F et al. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res 2002; 62: 2567-2575.
42. Huber P et al. Genomic structure and chromosomal mapping of the mouse VE-cadherin gene (Cdh5). Genomics 1996; 32: 21-28.
43. Gory S et al. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem 1998; 273: 6750-6755.
44. Gory S et al. The vascular endothehal-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood 1999; 93:184-192.
45. Lelievre E et al. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene 2000; 19: 2438-2446.
46. Garlanda C et al. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothehal cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 1994; 91: 7291-7295.
47. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
48. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
49. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89: 175-184.
50. Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
51. Pramudji C et al. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 2001; 7: 4272-4279.
52. Mavria G, Porter CD. Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment. Gene Ther 2001; 8: 913-920.
53. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: An update. Apoptosis 2002; 7: 475-482.
54. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
55. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997; 349: 2-3.
56. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir- mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
57. Vile RG et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
58. Frank DK, Frederick MJ, Liu TJ, Clayman GL. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck Clin Cancer Res 1998; 4: 2521-2528.
59. Gough MJ et al. Macrophages orchestrate the immune response to tumor cell death. Cancer Res 2001; 61: 7240-7247.
60. Kaneko Y, Tsukamoto A. Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett 1995; 96-105-110.
61. Melcher A et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-587.
62. Canfield V, West AB, Goldenring JR, Levenson R. Genetic ablation of parietal cells in transgenic mice: a new model for analyzing cell lineage relationships in the gastric mucosa. Proc Natl Acad Sci USA 1996; 93: 2431-2435.
63. Liu CS et al. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 2001; 3: 145-152.
64. Hayashi K, Hayashi T, Sun HD, Takeda Y. Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin. Cancer Gene Ther 2000; 7: 45-52.
65. Valerie K et al. Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 2001; 8: 3-8.
66. Kanazawa T et al. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ ganciclovir on cancer cells. Cancer Gene Ther 2001; 8: 99-106.
67. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
68. Bainbridge JW et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002; 9: 320-326.
69. Liu Y et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-173.
70. Uyechi LS, Gagne L, Thurston G, Szoka Jr FC. Mechanism of lipoplex gene delivery in mouse lung: binding and internalization of fluorescent lipid and DNA components. Gene Ther 2001; 8: 828-836.
71. Schlaeger TM et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997; 94: 3058-3063.
72. Kappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999; 93: 4284-4292.
73. Tybulewicz VL et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abI proto-oncogene. Cell 1991; 65: 1153-1163.
74. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press: New York, NY, 1994.
75. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989.
76. Al-Shawi R et al. A Mup promoter-thymidine kinase reporter gene shows relaxed tissue- specific expression and confers male sterility upon transgenic mice. Mol Cell Biol 1988; 8: 4821-4828.
77. al-Shawi R et al. The herpes simplex virus type 1 thymidine kinase is expressed in the testes of transgenic mice under the control of a cryptic promoter. Mol Cell Biol 1991; 11: 4207-4216.
78. Vittet D et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 1996; 88: 3424-3431.
79. Vermeulen PB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1999; 32A: 2474-2484.
80. Filleur S et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001; 15: 1373-1382.